Clinical and technical evaluation of ACS(TM)BR serum assay of MUC1 gene- derived glycoprotein in breast cancer, and comparison with CA 15-3 assays

Clinical Chemistry

Volumn 43, Issue 4, 1997, Pages 585-593

  Bon, Gijsbert G ^a   Von Mensdorff Pouilly, Silvia ^a   Kenemans, Peter ^a   Van Kamp, Gerard J ^a   Verstraeten, Rob A ^a   Hilgers, Jo ^a   Meijer, Sybren ^a   Vermorken, Jan B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemiluminescence immunoassay; method comparisons; monoclonal antibodies; mucin glycoprotein; polymorphic epithelial mucin; ROC curve analysis; tumor markers

Indexed keywords

CA 15-3 ANTIGEN; EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MUCIN; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOLUMINESCENCE; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; QUANTITATIVE ASSAY; RADIOIMMUNOASSAY; RELIABILITY; REPRODUCIBILITY;

CHIRON;

EID: 0030910604     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.4.585     Document Type: Article

References (25)

1. Zotter S, Hageman P, Lossnitzer L, Mooi W, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. In: Hilgers J, Zotter S, eds. Polymorphic epithelial mucin and CA-125-bearing glycoprotein as tumor-associated antigens. Cancer Rev 1988:11/12:55-101.
2. Gendler S, Lancaster C, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265:5573-8.
3. Hilkens J, Ligtenberg M, Vos H, Litvinov S. The structure of cell-associated mucin-like molecules and their adhesion modulating property. Trends Biochem Sci 1992;17:359-63.
4. Bon G, Kenemans P, van Kamp G, Yedema C, Hilgers J. Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med Allied Sci 1990;34(Suppl 3):151-62.
5. Tobias R, Rothwell C, Wagner J, Green A, Liu Y-SV. Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 [Abstract]. Clin Chem 1985;31:986.
6. Kufe DG, Inghirami M, Abe D, Hayes H, Justi-Wheeler H, Schlom H. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3:223-6.
7. Hilkens J, Buijs F, Hilgers J, Hageman Ph, Calafat J, Sonnenberg A, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors, Int J Cancer 1984;34:197-206.
8. Hilgers J, Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P. Quantification of polymorphic epithelial mucin: a challenge for biochemists and immunologists. Scand J Clin Lab Invest 1995; 55(Suppl 221):81-6.
9. Shostek D, Maimonis P, Girard A, Brasier J, Peterson J. An immunoassay for breast cancer antigen on the Ciba Corning ACS:180® Automated Chemiluminescence System. Clin Biochem Rev 1993;14:324.
10. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker M. Epitope mapping of Mab B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for the human MUC 1 gene. J Tumor Marker Oncol 1992;7:19-27.
11. Jaworek D, Zepke D, Hauber R. Technical and clinical evaluation of a new automated CA 15-3 test. In: Klapdor R, ed. Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Cancer of the breast - state and trends in diagnosis and therapy. Munchen: W. Zuckschwerdt Verlag, 1992:259-63.
12. van Kamp G, Bon G, Verstraeten R, Lynch D, Krikau M, Fluckiger J, et al. A multicenter evaluation of the Abbott IMx® CA 15-3™ assay. Clin Chem 1996;42:28-33.
13. Kirkwood BR. Essentials of medical statistics. Oxford (UK): Black-well Scientific Publications, 1990;60-4.
14. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. Clin Chem 1993;39:561-77.
15. Pons-Anicet D, Krebs B, Mira R, Namer M. Value of CA 15-3 in the follow-up of breast cancer patients. Br J Cancer 1987;55:567-9.
16. Hayes D, Zurawski V, Kufe D. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
17. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo J, Bodi R, Salvador L. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
18. Dogliotti L, Faggiuolo R, Buniva T, Berruti A, Torta M, Tampellini M. Serum CA 15-3 evaluation in breast cancer - personal experience. J Nucl Med Allied Sci 1990;34(Suppl 3):211-6.
19. Bon G, Kenemans P, Yedema C. van Kamp G, Nijman H, Hilgers J. Clinical relevance of the tumor marker CA 15-3 in the management of cancer patients. In: Crommelin D, Schellekens H. eds. From clone to clinic. Amsterdam: Kluwer Academic Publishers, 1990:111-22.
20. Tomlinson IPM, Whyman A, Barrett JA, Kremer JA. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur J Cancer 1995;31A:899-902.
21. Bon GG, Verheijen RHM, Zuetenhorst JM, van Kamp GJ, Verstraeten AA, Kenemans P. Mucin-like carcinoma-associated antigen (MCA) serum levels in patients with adenocarcinomas from ovary, breast and colon. Gynecol Obstet Invest 1996;42:58-62.
22. Yedema CA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW, Thomas CM, et al. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix, Int J Cancer 1991;47:170-9.
23. Bon G, Kenemans P, Verstraeten R, van Kamp G, Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996;174:107-14.
24. Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 assays, Int J Cancer 1988;3(Suppl):61-7.
25. Dnistrian AM, Schwartz MK, Greenberg EJ, Schwartz DC. BR27.29 as a marker in breast cancer. J Tumor Marker Oncol 1995;10(4): 91-7.